Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T83059
(Former ID: TTDI01798)
|
|||||
Target Name |
Tankyrase (TNKS)
|
|||||
Gene Name |
NO-GeName
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 4 Target-related Diseases | + | ||||
1 | Breast cancer [ICD-11: 2C60-2C6Y] | |||||
2 | Ovarian cancer [ICD-11: 2C73] | |||||
3 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
4 | Brain cancer [ICD-11: 2A00] | |||||
Function |
Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation (PARsylation) of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates PARsylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates PARsylation of TERF1, thereby contributing to the regulation of telomere length. Involved in centrosome maturation during prometaphase by mediating PARsylation of HEPACAM2/MIKI. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles. May be involved in spindle pole assembly through PARsylation of NUMA1. Stimulates 26S proteasome activity.
Click to Show/Hide
|
|||||
BioChemical Class |
Glycosyltransferases
|
|||||
UniProt ID |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 3 Clinical Trial Drugs | + | ||||
1 | 2X-121 | Drug Info | Phase 2 | Breast cancer | [1] | |
2 | BGB-290 | Drug Info | Phase 2 | Ovarian cancer | [2] | |
3 | STP1002 | Drug Info | Phase 1 | Solid tumour/cancer | [3] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 2 Inhibitor drugs | + | ||||
1 | 2X-121 | Drug Info | [1] | |||
2 | STP1002 | Drug Info | [5] | |||
Modulator | [+] 1 Modulator drugs | + | ||||
1 | BGB-290 | Drug Info | [4] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 2 | ClinicalTrials.gov (NCT03933761) Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE). U.S. National Institutes of Health. | |||||
REF 3 | ClinicalTrials.gov (NCT04505839) First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors. U.S. National Institutes of Health. | |||||
REF 4 | National Cancer Institute Drug Dictionary (drug id 769217). | |||||
REF 5 | Design and development of a tankyrase inhibitor STP06-1002 as an anticancer therapeutic agent. Cancer Res 2017;77(13 Suppl):Abstract nr 5171. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.